// App-Quantinova.ai

OP0005 : EFFECT OF BIOLOGIC AGENTS ON LIPIDS AND CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS

Researchers

Presenter

  • D. A. Pappas

Principal Investigators

  • A. John

  • J. Kremer

  • G. Reed

  • J. Greenberg

  • A. Shewade

  • D. H. Solomon

  • J. R. Curtis

Medical Centers

  • Columbia University, New York, NY

  • Albany Medical Center, Albany, NY

  • University of AL - Birmingham, AL, United States

  • New York University School of Medicine, New York, NY

  • Harvard Medical School, Boston, MA

  • University of Massachusetts, Worcester, Worcester, MA

Locations

  • United States

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Inflammatory Arthritis

  • Rheumatoid arthritis

  • Diabetes

Biomarkers

  • High sensitivity C-reactive protein

  • Tumor necrosis factor

  • Body mass index

Drug/Treatment

  • Tocilizumab

  • Abatacept

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved